Global Active Pharmaceutical Ingredients (API) Market – Industry Trends and Forecast to 2024

  • Published On : 06-11-2017
  • Published By : Data Bridge Market Research
  • No. of Pages : 350 Pages

The Global Active Pharmaceutical Ingredients (API) Market accounted to USD 155.1 billion in 2016 growing at a CAGR of 6.50% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2014, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Market Definition: Global Active Pharmaceutical Ingredients (API) Market

Active Pharmaceutical ingredients are central ingredient or chemical utilized as a part in manufacturing pharmaceutical medications. It consists of certain steps by procedures, such as chemical synthetic, recombinant DNA or other biotechnology techniques, maturation process, segregation from natural sources or any of these combinations.

Major Market Drivers and Restraints: Global Active Pharmaceutical Ingredients (API) Market

  • Rising geriatric population
  • Expansion in frequency of chronic diseases
  • Increment in Abbreviated New Medication Applications (ANDA)
  • Growth in technological advancement
  • Unfavourable medication value and policies
  • Stringent administrative prerequisites

Market Segmentation: Global Active Pharmaceutical Ingredients (API) Market

On the basis of product type, Active Pharmaceutical Ingredients (API) market is segmented into innovative and generic product.In 2015 innovative products dominatedthe market but in future period generic product will dominate growth in the market due to patent expiration of various renowned drugs as the manufacturer facedhuge losses.

On the basis of manufacture, active pharmaceutical ingredients(API) market is segmented into captive and merchant. Here merchant segment will be dominating in forecastperiod because of expansion in outsourcing with different units for the formulation of active drug ingredients and need not to invest in manufacturing sectors.

Based on synthesis, active pharmaceutical ingredients(API) market is segmented into synthetic and biotech. In 2015, synthetic segment was leading with the largest market share. The rising demand for protein based therapeutics and increase in R&D techniques will definitely contribute towards growth in the forecast period.

On the basis of product, active pharmaceutical ingredients(API)market is segmented intomAb and hormone. Based on drug, active pharmaceutical ingredients (API) market is segmented into OTC and RX.

On the basis of therapy, active pharmaceutical ingredients (API)market is segmented into diabetes, oncology, CNS, and CVD.

On the basis of geography, active pharmaceutical ingredients (API)market  report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, andBrazil among others. In 2017, North America is expected to dominate the market.

Competitive Analysis: Global Active Pharmaceutical Ingredients (API) Market

The Active Pharmaceutical Ingredients (API) Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of active pharmaceutical ingredients(API) marketfor global, Europe, North America, Asia Pacific and South America.

Major Market Competitors: Global Active Pharmaceutical Ingredients (API) Market

Some of the major players operating in active pharmaceutical ingredients (API) market  are Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., GlaxoSmithKline plc, Novartis International AG, Dr. Reddy’s Laboratories Ltd., AbbVie Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Sun Pharmaceutical Industries Limited, Aurobindo Pharma, Lupin, Albemarle Corporation,and Mylan N.V., among others.